Literature DB >> 21183291

Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia.

David J Carlson1, Paul J Keall, Billy W Loo, Zhe J Chen, J Martin Brown.   

Abstract

PURPOSE: Tumor hypoxia has been observed in many human cancers and is associated with treatment failure in radiation therapy. The purpose of this study is to quantify the effect of different radiation fractionation schemes on tumor cell killing, assuming a realistic distribution of tumor oxygenation. METHODS AND MATERIALS: A probability density function for the partial pressure of oxygen in a tumor cell population is quantified as a function of radial distance from the capillary wall. Corresponding hypoxia reduction factors for cell killing are determined. The surviving fraction of a tumor consisting of maximally resistant cells, cells at intermediate levels of hypoxia, and normoxic cells is calculated as a function of dose per fraction for an equivalent tumor biological effective dose under normoxic conditions.
RESULTS: Increasing hypoxia as a function of distance from blood vessels results in a decrease in tumor cell killing for a typical radiotherapy fractionation scheme by a factor of 10(5) over a distance of 130 μm. For head-and-neck cancer and prostate cancer, the fraction of tumor clonogens killed over a full treatment course decreases by up to a factor of ∼10(3) as the dose per fraction is increased from 2 to 24 Gy and from 2 to 18 Gy, respectively.
CONCLUSIONS: Hypofractionation of a radiotherapy regimen can result in a significant decrease in tumor cell killing compared to standard fractionation as a result of tumor hypoxia. There is a potential for large errors when calculating alternate fractionations using formalisms that do not account for tumor hypoxia.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21183291      PMCID: PMC3053128          DOI: 10.1016/j.ijrobp.2010.10.007

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  48 in total

1.  Comments on "Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer".

Authors:  Alexandru Daşu; Jack F Fowler
Journal:  Phys Med Biol       Date:  2005-03-21       Impact factor: 3.609

2.  Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy.

Authors:  Clint Park; Lech Papiez; Shichuan Zhang; Michael Story; Robert D Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-01       Impact factor: 7.038

3.  High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions.

Authors:  Yoshiya Yamada; Mark H Bilsky; D Michael Lovelock; Ennapadam S Venkatraman; Sean Toner; Jared Johnson; Joan Zatcky; Michael J Zelefsky; Zvi Fuks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-01-30       Impact factor: 7.038

4.  Combined use of Monte Carlo DNA damage simulations and deterministic repair models to examine putative mechanisms of cell killing.

Authors:  David J Carlson; Robert D Stewart; Vladimir A Semenenko; George A Sandison
Journal:  Radiat Res       Date:  2008-04       Impact factor: 2.841

5.  High-dose single-fraction radiotherapy: exploiting a new biology?

Authors:  J Martin Brown; Albert C Koong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-06-01       Impact factor: 7.038

6.  Effects of oxygen on intrinsic radiation sensitivity: A test of the relationship between aerobic and hypoxic linear-quadratic (LQ) model parameters.

Authors:  David J Carlson; Robert D Stewart; Vladimir A Semenenko
Journal:  Med Phys       Date:  2006-09       Impact factor: 4.071

7.  Optimum overall times II: Extended modelling for head and neck radiotherapy.

Authors:  J F Fowler
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-12-26       Impact factor: 4.126

8.  A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02).

Authors:  R E Drzymala; T H Wasserman; M Won; E Shaw; A J Cmelak; J Loeffler; L Souhami
Journal:  Radiother Oncol       Date:  2008-03-14       Impact factor: 6.280

9.  The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography.

Authors:  Zhixiong Lin; James Mechalakos; Sadek Nehmeh; Heiko Schoder; Nancy Lee; John Humm; C Clifton Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-15       Impact factor: 7.038

10.  The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction.

Authors:  David J Brenner
Journal:  Semin Radiat Oncol       Date:  2008-10       Impact factor: 5.934

View more
  48 in total

1.  EGFR Mutations Compromise Hypoxia-Associated Radiation Resistance through Impaired Replication Fork-Associated DNA Damage Repair.

Authors:  Mohammad Saki; Haruhiko Makino; Prashanthi Javvadi; Nozomi Tomimatsu; Liang-Hao Ding; Jennifer E Clark; Elaine Gavin; Kenichi Takeda; Joel Andrews; Debabrata Saha; Michael D Story; Sandeep Burma; Chaitanya S Nirodi
Journal:  Mol Cancer Res       Date:  2017-08-11       Impact factor: 5.852

Review 2.  Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data.

Authors:  Nitin Ohri; Adam P Dicker; Yaacov Richard Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-19       Impact factor: 7.038

Review 3.  Molecular imaging of tumor hypoxia with positron emission tomography.

Authors:  Olivia J Kelada; David J Carlson
Journal:  Radiat Res       Date:  2014-03-27       Impact factor: 2.841

4.  Differential response to ablative ionizing radiation in genetically distinct non-small cell lung cancer cells.

Authors:  Ayman Oweida; Zeinab Sharifi; Hani Halabi; Yaoxian Xu; Siham Sabri; Bassam Abdulkarim
Journal:  Cancer Biol Ther       Date:  2016-04-02       Impact factor: 4.742

Review 5.  The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?

Authors:  J Martin Brown; David J Carlson; David J Brenner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-02-01       Impact factor: 7.038

Review 6.  Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.

Authors:  Feng Liu; An Tai; Percy Lee; Tithi Biswas; George X Ding; Isaam El Naqa; Jimm Grimm; Andrew Jackson; Feng-Ming Spring Kong; Tamara LaCouture; Billy Loo; Moyed Miften; Timothy Solberg; X Allen Li
Journal:  Radiother Oncol       Date:  2016-11-18       Impact factor: 6.280

7.  In regards to decision making for reirradiation of a recurrent intramedullary spinal cord metastasis.

Authors:  Charles E Rutter; James B Yu; David J Carlson; Zain A Husain; Sherry Zhao; James Picone; Ranjit S Bindra
Journal:  J Radiosurg SBRT       Date:  2014

8.  Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules.

Authors:  Jeho Jeong; Jung Hun Oh; Jan-Jakob Sonke; Jose Belderbos; Jeffrey D Bradley; Andrew N Fontanella; Shyam S Rao; Joseph O Deasy
Journal:  Clin Cancer Res       Date:  2017-05-24       Impact factor: 12.531

9.  Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy.

Authors:  Xiaowen Sun; Lei Deng; You Lu
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

Review 10.  Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era.

Authors:  Everett J Moding; Yvonne M Mowery; David G Kirsch
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.